Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis

Cipriani, Andrea; Zhou, Xinyu; Giovane, Cinzia Del; Hetrick, Sarah; Qin, Bin; Whittington, Craig; Coghill, David; Zhang, Yuqing; Hazell, Philip; Leucht, Stefan; Cuijpers, Pim; Pu, Juncai; Cohen, Doron; Ravindran, Arun; Liu, Yiyun; Michael, Kurt D.; Yang, Lining; Liu, Lanxiang; Xie, Peng

doi:10.1016/s0140-6736(16)30385-3

Cited by 557 publications

(424 citation statements)

References 32 publications

Supporting

Mentioning

373

Contrasting

Unclassified

Order By: Relevance

“…A recent NMA compared antidepressants, based on indirect comparisons across studies, again found the drug-placebo difference to be greatest for fluoxetine (SMD 0.51) 26. The study did not find a significant difference between fluoxetine and other NGAs, although these findings are constrained by methodological issues 27.…”

Section: Introductionmentioning

confidence: 87%

Recent developments in the treatment of major depressive disorder in children and adolescents

Hussain

Dubicka

Wilkinson

2018

Evid Based Mental Health

View full text Add to dashboard Cite

Major depressive disorder in adolescents is an important public health concern. It is common, a risk factor for suicide and is associated with adverse psychosocial consequences. The UK National Institute for Health and Care Excellence guidelines recommend that children and young people with moderate-to-severe depression should be seen within Child and Adolescent Mental Health Services and receive specific psychological interventions, possibly in combination with antidepressant medication. Cognitive behavioural therapy (in some studies) and interpersonal psychotherapy have been demonstrated to be more effective than active control treatments for depressed adolescents. For children with depression, there is some evidence that family focused approaches are more effective than individual therapy. Fluoxetine is the antidepressant with the greatest evidence for effectiveness compared with placebo. Treatment with antidepressants and/or psychological therapy is likely to reduce suicidality, although in some young people, selective serotonin reuptake inhibitors lead to increased suicidality. There is limited evidence that combination of specific psychological therapy and antidepressant medication is better than treatment with monotherapy. There are methodological limitations in the published literature that make it difficult to relate study findings to the more severely ill clinical population in Child and Adolescent Mental Health Services. Young people should have access to both evidence-based psychological interventions and antidepressants for paediatric depression. Collaborative decisions on treatment should be made jointly by young people, their carers and clinicians, taking into account individual circumstances and potential benefits, risks and availability of treatment.

show abstract

Section: Introductionmentioning

confidence: 87%

Recent developments in the treatment of major depressive disorder in children and adolescents

Hussain

Dubicka

Wilkinson

2018

Evid Based Mental Health

View full text Add to dashboard Cite

show abstract

“…Similarly, the use of SNRIs in young depressed patients (7-18) did not produce better therapeutic effects than a placebo treatment, though duloxetine has shown therapeutic potential in such patients [92]. A metaanalysis of the efficacy of venlafaxine, duloxetine, fluoxetine, and imipramine in children and adolescents found that SNRIs and tricyclic antidepressants do not seem to offer a significant advantage in treating major depression disorder in this population, as only fluoxetine produced an adequate therapeutic effect in those patients [93].…”

Section: Active Compound Therapeutic Use Referencementioning

confidence: 99%

Association of 5-HT1A Receptors with Affective Disorders

Soria-Fregozo¹,

Vega²,

FranciscoRodríguez-Landa³

et al. 2017

Serotonin - A Chemical Messenger Between All Types of Living Cells

View full text Add to dashboard Cite

Serotonin or 5-hydroxytryptamine (5-HT) is synthesized in both the brain and peripheral system, which exert their actions at a wide family of receptors classified as 5-HT 1 to 5-HT 7 . Pharmacological, behavioral, and clinical studies involve particularly to the 5-HT 1A receptors (5-HT 1A -R) -auto-receptors (presynaptic) and heteroreceptors (postsynaptic) -in the control of motivated behavior, and consequently in the physiopathology of affective disorders and in the action mechanism of antidepressant drugs. In this way, some research support that 5-HT 1A -R participates in the delayed effect of different types of antidepressants, including selective serotonin reuptake inhibitors (SSRIs), and tricyclic drugs, principally. The therapeutic effect of serotonergic drugs as the SSRIs, starting with the binding to auto-receptors, which produces increases of 5-HT in the synaptic cleft as consequence of blockade of serotonin reuptake. While these molecular events occur initially, in the long-term are produced plastic changes at neuronal level, as well as down-regulation of the 5-HT 1A -R, which is associated with the therapeutic effects of antidepressant drugs. The purpose of this chapter is to analyze and discuss the current information about of 5-HT 1A -R-mediated signaling cascades, the intracellular signaling of 5-HT 1A -R, in addition to their expression and pharmacology that are important to treatment of affective disorders symptoms.

show abstract

“…A general recommendation for adult patients is to use fluoxetine or sertraline for depression in DM suffering patients 64 . In terms of reducing depressive symptoms and improving functioning amongst children suffering from depression, fluoxetine is probably the best option to consider for pharmacological treatment for children and adolescents 65 , even if there are some safety concerns and there are no valid research studies to base recommendations on. The effectiveness of antidepressants in treating anxiety and depressive disorders in paediatric DM has not been documented.…”

Section: Medicationmentioning

confidence: 99%

Anxiety and depressive disorders in children and adolescents suffering from diabetes mellitus

2018

View full text Add to dashboard Cite

Abstract. Diabetes mellitus (DM) and mental health problems are frequently co-occurring conditions. Anxiety and depressive disorders are the most common mental disorders that accompany DM. These conditions could have severe consequences in children and adolescents suffering from DM. Thus, it is important to pay additional attention to them. This article provides an overview of prevalence rates of DM and co-occurring anxiety and depression, as well as understanding the etiology and treatment options for anxiety and depressive disorders in children and adolescents with DM. Key words: anxiety disorders; depression; diabetes mellitusSažetak. Diabetes mellitus (DM) i psihički poremećaji često su u komorbiditetu. Anksiozni i depresivni poremećaji najčešći su duševni poremećaji koji prate DM. Ovi mentalni poremećaji mogu imati ozbiljne posljedice za djecu i adolescente koji boluju od DM-a, stoga je važno posvetiti im dodatnu pozornost. U radu donosimo kratak pregled prevalencije DM-a i komorbiditetnih anksioznih i depresivnih poremećaja te razumijevanje etioloških karakteristika. Ukratko smo se osvrnuli i na mogućnosti liječenja djece i adolescenata koji imaju DM i anksiozni odnosno depresivni poremećaj. Ključne riječi: anksiozni poremećaji; depresivni poremećaji; diabetes mellitusMini-review/Kratki pregledni članak 1 Odsjek za psihologiju, Filozofski fakultet, Sveučilište u Rijeci, Rijeka 2 Klinika za neurologiju i psihijatriju za decu i omladinu, Beograd, Srbija 3 Katedra za psihijatriju i psihološku medicinu, Medicinski fakultet, Sveučilište u Rijeci, Rijeka

show abstract

Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis

Abstract: National Basic Research Program of China (973 Program).

Cited by 557 publications

References 32 publications

Recent developments in the treatment of major depressive disorder in children and adolescents

Recent developments in the treatment of major depressive disorder in children and adolescents

Association of 5-HT1A Receptors with Affective Disorders

Anxiety and depressive disorders in children and adolescents suffering from diabetes mellitus

Contact Info

Product

Resources

About